Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer | OncLive

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

July 22, 2020

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, chair, Tissue Committee, associate scientist, Experimental Therapeutics Program, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, UAB Medicine, discusses unmet needs in platinum-resistant ovarian cancer.

Significant progress has been made in the up-front maintenance setting for patients with platinum-sensitive or homologous recombination deficient–ovarian cancer, explains Arend.

Despite the recent advances that have been made in the ovarian cancer space, the majority of patients with ovarian cancer eventually experience recurrence and, ultimately, become platinum resistant, says Arend.

However, limited progress has been made for patients with platinum-resistant ovarian cancer. Future preclinical and clinical trials should be aimed at prolonging survival for these patients, concludes Arend.


x